Genetic diversity of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-3 in a hypoendemic transmission environment

Am J Trop Med Hyg. 2009 Mar;80(3):479-86.

Abstract

The N-terminal domain of Plasmodium falciparum merozoite surface protein-3 (PfMSP3) has been excluded from malaria vaccine development largely because of genetic diversity concerns. However, no study to date has followed N-terminal diversity over time. This study describes PfMSP3 variation in a hypoendemic longitudinal cohort in the Peruvian Amazon over the 2003-2006 transmission seasons. Polymerase chain reaction was used to amplify the N-terminal domain in 630 distinct P. falciparum infections, which were allele-typed by size and also screened for sequence variation using a new high-throughput technique, denaturing high performance liquid chromatography. PfMSP3 allele frequencies fluctuated significantly over the 4-year period, but sequence variation was very limited, with only 10 mutations being identified of 630 infections screened. The sequence of the PfMSP3 N-terminal domain is relatively stable over time in this setting, and further studies of its status as a vaccine candidate are therefore warranted.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Antigens, Protozoan / genetics*
  • Antigens, Protozoan / immunology*
  • Chromatography, High Pressure Liquid
  • Endemic Diseases / prevention & control
  • Female
  • Gene Frequency
  • Genetic Variation*
  • Humans
  • Malaria Vaccines / immunology*
  • Malaria, Falciparum / prevention & control*
  • Malaria, Falciparum / transmission
  • Male
  • Plasmodium falciparum / genetics
  • Plasmodium falciparum / immunology*
  • Protein Structure, Tertiary
  • Protozoan Proteins / genetics*
  • Protozoan Proteins / immunology*
  • Young Adult

Substances

  • Antigens, Protozoan
  • Malaria Vaccines
  • Protozoan Proteins
  • merozoite surface protein 3, Plasmodium